Cover Image

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Licia Uccelli (Author), Alessandra Boschi (Author), Corrado Cittanti (Author), Petra Martini (Author), Stefano Panareo (Author), Eugenia Tonini (Author), Alberto Nieri (Author), Luca Urso (Author), Matteo Caracciolo (Author), Luca Lodi (Author), Aldo Carnevale (Author), Melchiore Giganti (Author), Mirco Bartolomei (Author)
Format:	Book
Published:	MDPI AG, 2021-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
by: Luca Urso, et al.
Published: (2022)

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023)

Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations
by: Klaudia Siwowska, et al.
Published: (2019)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021)

In Vitro Biological Evaluation of Aprepitant Based <sup>177</sup>Lu-Radioconjugates
by: Paweł K. Halik, et al.
Published: (2022)

Liquid Chromatography ICP-MS to Assess the Stability of <sup>175</sup>Lu- and <sup>nat</sup>Ga-Based Tumor-Targeting Agents towards the Development of <sup>177</sup>Lu- and <sup>68</sup>Ga-Labeled Radiopharmaceuticals
by: Rahel H. Wallimann, et al.
Published: (2024)

[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
by: Berthold A. Nock, et al.
Published: (2023)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022)

Simultaneous Visualization of <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
by: Francesca Borgna, et al.
Published: (2021)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021)

Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of <sup>68</sup>Ga-, <sup>205/206</sup>Bi-, and <sup>177</sup>Lu-Labeled NAPamide-Based Radiopharmaceuticals
by: Dániel Szücs, et al.
Published: (2023)

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023)

Development and Validation of Analytical Methods for Radiochemical Purity of <sup>177</sup>Lu-PSMA-1
by: Pauline Orhon, et al.
Published: (2022)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023)

Synthesis, Characterization, and Therapeutic Efficacy of <sup>177</sup>Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
by: Dragana Stanković, et al.
Published: (2023)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022)

[<sup>177</sup>Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative <i>In Vitro</i> Autoradiography
by: Roswitha Tönnesmann, et al.
Published: (2019)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021)

Preparation, Radiolabeling with <sup>68</sup>Ga/<sup>177</sup>Lu and Preclinical Evaluation of Novel Angiotensin Peptide Analog: A New Class of Peptides for Breast Cancer Targeting
by: Subhani M. Okarvi
Published: (2023)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [<sup>177</sup>Lu]Lu-PP-F11N
by: Michal Grzmil, et al.
Published: (2021)

In Vitro Assessment of <sup>177</sup>Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
by: Ayça Tunçel, et al.
Published: (2024)

Combination of [<sup>177</sup>Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
by: Marina Simón, et al.
Published: (2022)

Brachytherapy Approach Using <sup>177</sup>Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model
by: Min-Ying Lin, et al.
Published: (2021)

Therapeutic Efficacy of <sup>177</sup>Lu-Labeled A20FMDV2 Peptides Targeting α<sub>ν</sub>β<sub>6</sub>
by: Truc Thao Huynh, et al.
Published: (2022)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023)

Nuclear Cross-Section of Proton-Induced Reactions on Enriched <sup>48</sup>Ti Targets for the Production of Theranostic <sup>47</sup>Sc Radionuclide, <sup>46c</sup>Sc, <sup>44m</sup>Sc, <sup>44g</sup>Sc, <sup>43</sup>Sc, and <sup>48</sup>V
by: Liliana Mou, et al.
Published: (2023)

Predictability of Invisalign<sup>®</sup> Clear Aligners Using OrthoPulse<sup>®</sup>: A Retrospective Study
by: Luca Levrini, et al.
Published: (2022)

Molecular analysis of T<sup>-</sup>B<sup>-</sup>NK<sup>+ </sup>severe combined immunodeficiency and Omenn syndrome cases in Saudi Arabia
by: Al-Kayal Fadi, et al.
Published: (2009)

Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations
by: Sven Hartmann, et al.
Published: (2022)

Role of CD4<sup>+</sup>CD25<sup>hi</sup>CD127<sup>lo/-</sup>FoxP3<sup>+</sup> regulatory T lymphocytes in the pathogenesis of Behçet's disease in children
by: Rosenzwajg M, et al.
Published: (2011)

Comparison of Flow and Compression Properties of Four Lactose-Based Co-Processed Excipients: Cellactose<sup>®</sup> 80, CombiLac<sup>®</sup>, MicroceLac<sup>®</sup> 100, and StarLac<sup>®</sup>
by: Martin Dominik, et al.
Published: (2021)

Digital Condylar Parameter Assessment Using Cadiax<sup>®</sup> 2 and Modjaw<sup>®</sup>
by: Smaranda Buduru, et al.
Published: (2024)

NAD<sup>+</sup> Homeostasis and NAD<sup>+</sup>-Consuming Enzymes: Implications for Vascular Health
by: Roberto Campagna, et al.
Published: (2023)